Stockwinners Market Radar for June 01, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT GREENWAVE TECHNOLOGY SOLUTIONS INC trading halted, news pending

18:27 EDT Zscaler CEO: We beat targets across all metrics in Q3 - In an interview on CNBC's Mad Money, Jay Chaudhry said Gen-AI is making it easier to perform more sophisticated phishing attacks. The company is winning larger customers because it can offer the Zero Trust platform, he noted. It recently won a seven figure deal with the Department of Defense. "Zscaler is not just a company, it's a mission," he added.

17:46 EDT Carbon Streaming appoints Christian Milau as interim CEO, to acquire Blue Dot - Carbon Streaming announced the following changes to its board of directors and senior management. The changes follow recent discussions between the board and certain of the company's shareholders, led by Marin Katusa, Justin Cochrane and Maurice Swan have resigned as directors of the company. Continuing as directors are Candace MacGibbon, Alice Schroeder and Jeanne Usonis. Christian Milau, Marcel de Groot and Olivier Garret have joined the board of Carbon Streaming. Milau has also been appointed interim CEO of the company. Garret has been appointed as chair of the board. Mr. Garret will Chair all committees of the board other than the audit committee and compensation committee. de Groot has been appointed as chair of the audit committee, and Schroeder will continue as chair of the compensation committee. Before Messrs. Milau, de Groot, and Garret joined the board, Carbon Streaming agreed to acquire Blue Dot Carbon Corp, a private company led by Milau, for a total purchase price of $2.5M, to be paid in common shares of Carbon Streaming. de Groot is a member of the board of directors of Blue Dot. The number of shares to be issued as consideration to Blue Dot shareholders will be settled 30 days after this announcement, using a 30-day VWAP to calculate the number of Shares, with a maximum consideration price of C$0.75 per share. Closing of this transaction is expected in July and is subject to any customary stock exchange or regulatory approvals. The acquisition of Blue Dot was approved by the board upon the unanimous recommendation of the special independent committee of the board, of which MacGibbon and Schroeder are members. Katusa facilitated the negotiation between Carbon Streaming and Blue Dot. Katusa is not a shareholder of Blue Dot, and no fees, in cash or in-kind, were paid in connection with this transaction. Blue Dot has an equity investment in a carbon project developer and certain option rights to invest in future removals projects of its partners.

17:16 EDT GE Aerospace awarded $438.62M Defense Logistics Agency contract - General Electric has been awarded a maximum $438.62M firm-fixed price, requirements-type contract for workload augmentation/offload support of F-110 engine modules supplies. This contract was a sole-source acquisition using justification 10 U.S. Code 3204 (c)(1), as stated in Federal Acquisition Regulation 6.302-1(a)(1). This is a four-year four-month base contract with one five-year option period. The performance completion date is September 30, 2028. Using military service is Air Force. Type of appropriation is fiscal 2024 through 2028 defense appropriated funds and working capital funds. The contracting activity is the Defense Logistics Agency Aviation.

16:32 EDT Starbucks announces Satya Nadella resigns from board of directors - In a regulatory filing, Starbucks stated, "On May 30, 2024, Satya Nadella informed Starbucks Corporation that he is resigning from the Board of Directors, effective immediately. Effective May 30, 2024, the size of the Board was reduced by one."

16:18 EDT Eaton makes strategic investment in NordicEPOD - Eaton announced it has completed a significant strategic investment in NordicEPOD AS, formerly a wholly-owned subsidiary of CTS Nordics, which designs and assembles standardized power modules for data centers in the Nordic region.

16:13 EDT Alpine Income Property names Philip Mays as CFO - Alpine Income Property Trust announced that Philip Mays has been appointed Senior Vice President, CFO and Treasurer of the company, effective as of June 17. Mays was most recently the CFO of Shadowbox Studios, from September 2021 to February 2024.

16:11 EDT Fusion Pharmaceuticals receives final court order approving AstraZeneca deal - Fusion Pharmaceuticals (FUSN) announced it has obtained a final order from the Ontario Superior Court of Justice approving the previously announced statutory plan of arrangement under Section 192 of the Canada Business Corporations Act, pursuant to which a wholly-owned subsidiary of AstraZeneca (AZN) will acquire all issued and outstanding shares of Fusion. Fusion shareholders will receive $21.00 per share in cash upfront on completion of the Arrangement plus a deferred payment on the achievement of a future regulatory milestone in the form of a contingent value right of $3.00 per share. As previously announced, Fusion's shareholders approved the Arrangement at a special meeting of Fusion's shareholders on May 29, 2024. The Arrangement is subject to customary closing conditions. Subject to the satisfaction of such conditions, the transaction is expected to be completed in the second quarter of 2024. Following closing of the Arrangement, Fusion's common shares will be delisted from Nasdaq.

16:06 EDT Autodesk reports results of audit investigation, names Betsy Rafael interim CFO - Autodesk announced the results of the Audit Committee investigation. As previously announced on April 1, 2024, the Audit Committee of the Board of Directors initiated an internal investigation regarding the company's free cash flow and non-GAAP operating margin practices. The Committee has completed its planned procedures with respect to the investigation. The company's management has determined that there will be no restatement or adjustment of any audited or unaudited, filed or previously announced, GAAP or non-GAAP financial statements. "We appreciate your patience as we work through this important process. We take situations like this very seriously and are grateful to put the investigation behind us," said Andrew Anagnost, Autodesk president and CEO. "In the first quarter of fiscal 2025, we generated broad-based growth in AEC and manufacturing across products and regions. The new transaction model implementation is on track. Our strong start sets us up well to achieve our goals for the year." The company also announces the following executive appointments. Elizabeth "Betsy" Rafael has been appointed by the Board as Interim Chief Financial Officer (Principal Financial Officer), effective May 31, 2024. As Interim Chief Financial Officer, she is not currently an "independent director" for purposes of the Nasdaq Stock Market and has stepped down from the Audit Committee. She remains a director of the company. Deborah L. Clifford has been appointed as the company's Chief Strategy Officer, reporting to the Chief Executive Officer, effective May 31, 2024. Her responsibilities will include, among other things, corporate development, new vertical businesses that are outside Autodesk's existing product groups, and the company's Social Impact and Sustainability efforts.

16:01 EDT Keurig Dr Pepper acquires strategic assets from Kalil Bottling Company, no terms - Keurig Dr Pepper announced an agreement to acquire all production, sales and distribution assets of independent bottler Kalil Bottling Co. With the agreement, KDP's company-owned direct-store-delivery operations will gain new bottling and distribution rights in Arizona to key KDP brands including Canada Dry, 7UP, A&W, Snapple and Core Hydration, servicing 7.4 million consumers and approximately 4,500 retail outlets. After the close of the transaction, KDP will operate a production facility in Tucson and sales and distribution centers in Tucson and Tempe. KDP expects to add approximately 425 employees in support of these new state-wide operations and will be working with Kalil to actively recruit from its existing talent base. The acquisition is expected to close in the third quarter of 2024. Terms of the agreement have not been disclosed.

14:57 EDT Boston Beer continues climb after report of Suntory takeover talks, now up 29%

14:46 EDT Boston Beer trading resumes

14:41 EDT Boston Beer trading halted, volatility trading pause

13:38 EDT Donaldson raises quarterly cash dividend 8% to 27c per share - Donaldson Company announced that its Board of Directors declared a regular cash dividend of 27c per share, an increase of 8.0% from the prior quarterly dividend of 25c per share. The dividend is payable June 28, 2024, to shareholders of record on June 17, 2024.

13:02 EDT Baker Hughes reports U.S. rig count unchanged at 600 rigs - Baker Hughes reports that the U.S. rig count is unchanged from last week at 600 with oil rigs down 1 to 496, gas rigs up 1 to 100 and miscellaneous rigs unchanged at 4. The U.S. Rig Count is down 96 rigs from last year's count of 696 with oil rigs down 59, gas rigs down 37 and miscellaneous unchanged. The U.S. Offshore Rig Count is up 1 to 22, up 2 year-over-year. The Canada Rig Count is up 8 from last week to 128, with oil rigs up 10 to 74, and gas rigs down 2 to 54. The Canada Rig Count is up 31 from last year's count of 97, with oil rigs up 23, and gas rigs up 8.

12:49 EDT WisdomTree says Glass Lewis recommends investors vote for proposals, directors - WisdomTree announced that Glass Lewis, an independent proxy advisory firm, has recommended that stockholders vote "FOR" all WisdomTree proposals, including "FOR" all nine members of WisdomTree's Board of Directors, including Anthony Bossone, Win Neuger and Jonathan Steinberg, at WisdomTree's 2024 Annual Meeting of Stockholders. Win Neuger, Chair of the WisdomTree Board of Directors, said, "We are pleased that Glass Lewis recognizes the value WisdomTree continues to deliver to its stockholders. After a careful review of the facts and meeting with representatives of WisdomTree's Board, Glass Lewis affirms that our current strategy is working and has resulted in strong financial results, peer-leading stockholder returns and momentum across our business, including through our growing digital assets strategy." Glass Lewis also reiterates the "invaluable institutional knowledge that Messrs. Neuger, Bossone and Steinberg bring to the Board, which has been significantly refreshed over the past three years," WisdomTree said. Glass Lewis determined that dissident stockholder ETFS Capital's arguments as part of its campaign to disrupt the Company's continued progress "are insufficient and unconvincing, and therefore, do not warrant shareholder opposition to Management Nominees Bossone, Neuger and Steinberg at this time."

12:29 EDT Denali Capital Acquisition Corp trading resumes

12:24 EDT Denali Capital Acquisition Corp trading halted, volatility trading pause

12:22 EDT Redwoods Acquisition Corp trading halted, volatility trading pause

12:21 EDT KalVista announces publication of data from Phase 3 KONFIDENT trial - KalVista Pharmaceuticals announced that late-breaking data from the pivotal phase 3 KONFIDENT trial and open label KONFIDENT-S extension trial evaluating the efficacy and safety of sebetralstat were presented as late-breaking presentations at the European Academy of Allergy and Clinical Immunology Congress 2024. The results of KONFIDENT were simultaneously published in The New England Journal of Medicine. As presented and published, the KONFIDENT trial met its primary and key secondary endpoints and demonstrated a safety profile no different from placebo. Median time from attack onset to treatment was 41 min with 55.7% of participants treating in less than 1 hour; 42.8% of attacks treated when still mild. Primary endpoint: Time to beginning of symptom relief was significantly faster than placebo; Median time to beginning of symptom relief was 1.61 hours with sebetralstat 300 mg, 1.79 hours with sebetralstat 600 mg, and 6.72 hours with placebo. Key secondary endpoints: Significantly faster time to a reduction in attack severity from baseline compared to placebo; Significantly faster time to complete attack resolution compared to placebo; Primary and key secondary endpoints were analyzed in a fixed, hierarchical sequence and adjusted for multiplicity. Subgroup analyses showed a consistency of treatment effect in among attacks regardless of attack severity, attack location, use of long-term prophylaxis, or geography. The safety of sebetralstat at both dose levels was no different than placebo. There were no patient withdrawals due to any adverse events and no treatment-related serious adverse events were observed. Treatment-related adverse event rates were 2.3% for 300 mg sebetralstat, 3.2% for 600 mg sebetralstat, and 4.8% for placebo. Phase 3 KONFIDENT-S Open-Label Extension Trial Interim Results: 112 participants enrolled; 15.2% aged 12-less than18 years, 81.3% aged 18-less than65 years, and 2.7% aged greater than or equal to65 years; 68.8% receiving on-demand treatment only; 31.3% receiving stable long-term prophylaxis; 649 attacks treated with sebetralstat; median 5.0 attacks treated per participant; Median time from attack onset to treatment was 9 minutes; Median time to beginning of symptom relief was 1.8 hours; Median times to reduction in attack severity and complete attack resolution were consistent with results in the KONFIDENT Trial. KONFIDENT and KONFIDENT-S are the first and only clinical trials ever to include complete symptom relief as an endpoint; all other trials use near-complete relief, which is a much lower standard that does not capture the entire attack sequence in the same manner. Laryngeal attack subgroup, median time to beginning of symptom relief was 1.3 hours.

12:13 EDT Plum Acquisition Corp I trading resumes

12:11 EDT Bite Acquisition Corp trading halted, volatility trading pause

12:04 EDT VF Corp. rises 12.3% - VF Corp. is up 12.3%, or $1.51 to $13.85.

12:02 EDT Gap rises 26.0% - Gap is up 26.0%, or $5.86 to $28.38.

12:01 EDT SentinelOne falls -14.9% - SentinelOne is down -14.9%, or -$2.88 to $16.54.

12:00 EDT Dell Technologies falls -22.2% - Dell Technologies is down -22.2%, or -$37.72 to $132.20.

11:47 EDT Valneva announces positive CHMP opinion for chikungunya vaccine - Valneva announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending authorization of Valneva's single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. If approved, it will become the first chikungunya vaccine available in Europe to address this unmet medical need, the company said in a statement. Valneva is also preparing a marketing authorization application for submission to the UK Medicines and Healthcare products Regulatory Agency.

11:43 EDT New Providence Acquisition Corp II trading resumes

11:39 EDT Western Acquisition Ventures Corp trading halted, volatility trading pause

11:34 EDT F9 Investments urges LL Flooring shareholders to vote for director nominees - F9 Investments, which together with its affiliates collectively owns approximately 8.85% of LL Flooring Holdings common stock and is the Company's largest shareholder, filed definitive proxy materials with the Securities and Exchange Commission for the election of three independent director candidates,Thomas D. Sullivan, John Jason Delves, and Jill Witter, to LL Flooring's Board of Directors at the Company's 2024 Annual Meeting of Shareholders to be held on July 10, 2024. In connection with the filing of definitive proxy materials, F9 is mailing a letter to LL Flooring's shareholders, which read in part, "We are deeply concerned about the severe value erosion of our investment and the utter lack of urgency and engagement demonstrated by the Company's entrenched Board of Directors. LL Flooring has vastly underperformed its peer group and broader market indices by a shockingly wide margin over all relevant time periods, and the Company's stock price is down more than 57% this year alone. As a result of the Board's many failures, the survival of this former industry leader is now in extreme peril, further evidenced by the negative "going concern" opinion recently issued by the Company's auditors. Simply put, shareholders deserve an immediate change of course. Accordingly, we have nominated three highly qualified directors to LL Flooring's Board in connection with the upcoming 2024 Annual Meeting of Shareholders, scheduled for July 10, 2024...LL Flooring is in dire need of a lifeline. Shareholders should not expect meaningful change from a Board that has failed to deliver on its promises for years. Now is the moment to have your voice heard and to protect your investment."

11:07 EDT Caesars jumps 9% to $34.66 after Bloomberg report of Icahn stake

11:03 EDT Otter Tail receives MPUC approval on integrated resource plan - The Minnesota Public Utilities Commission approved Otter Tail Power's, a wholly-owned subsidiary of Otter Tail Corporation, resource plan containing many elements of the settlement between Otter Tail Power and other parties filed April 2, 2024, in the company's 2022-2036 Integrated Resource Plan docket. The MPUC decision: Allows Otter Tail Power to retain the reliability benefits of Coyote Station while running the portion of the plant used to serve the company's Minnesota customers for emergency purposes only. This will begin as soon as June 1, 2026, and end no later than 2031. At that time, the company's Minnesota customers will no longer use the capacity of or energy from Coyote Station. The MPUC's decision doesn't require the company to withdraw from Coyote Station or change how the company operates Coyote Station to serve its North Dakota and South Dakota customers, even beyond 2031. Allows the company to begin creating project plans for replacement energy for the portion of Coyote Station used to serve the company's Minnesota customers-and allows the company to make progress toward the Minnesota Carbon Free standard. Otter Tail Power will develop plans for 200 to 300 MW of solar resources, 150 to 200 MW of wind resources, and 20 to 75 MW of battery storage to be commercially operational between now and the end of 2029. Recognizes Otter Tail's proposal to add on-site liquefied natural gas storage at its Astoria Station natural gas facility, a shared resource across the company's three-state service area, is reasonable and prudent to protect system reliability and provide price protection for the company's Minnesota customers. This recognition takes the company one step farther in the regulatory process to add on-site fuel at Astoria Station.

10:49 EDT Paycom reports Christopher Thomas resigned as co-CEO - As previously reported, Paycom announced that Randy Peck has been appointed to serve as Paycom's COO. Separately, in a regulatory filing, Paycom disclosed that on May 29, for "personal reasons," Christopher Thomas resigned from his position as Co-Chief Executive Officer of the company, effective immediately. Chad Richison will continue to lead the company as Chief Executive Officer, President and Chairman of the Board of Directors, the filing noted. In Friday morning trading, Paycom shares are down $7.39, or nearly 5%, to $151.56. Reference Link

10:06 EDT Walmart expands InHome delivery service to additional 10M U.S. households - Walmart is announcing the expansion of its InHome delivery service to an additional 10M U.S. households, including those in California. "Customers in San Bernardino, Riverside and Ontario will now have access to the ultimate in delivery convenience. InHome is designed to be a time saver for customers by delivering fresh groceries and everyday essentials to their doorstep or unpacking items directly into their kitchen or garage refrigerators. In addition to the San Bernardino market, Walmart is expanding the service today to also include customers in Boston, Detroit, Minneapolis and Philadelphia, bringing the total scale of InHome to more than 50 markets covering over 45 million homes," the company stated.

10:03 EDT Genesco rises 13.9% - Genesco is up 13.9%, or $3.80 to $31.10.

10:01 EDT Veeva falls -9.2% - Veeva is down -9.2%, or -$17.85 to $176.34.

10:00 EDT Bristol Myers' Breyanzi approved by FDA as new CAR T cell therapy in MCL - Bristol Myers Squibb announced yesterday that the U.S. FDA has granted approval for Breyanzi, a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor. "This FDA approval marks the fourth distinct subtype of non-Hodgkin lymphoma for which Breyanzi is approved, making it the CAR T cell therapy available to treat the broadest array of B-cell malignancies," the company stated. "With Breyanzi, we are delivering on the promise of cell therapy by offering a definitive treatment option for some of the most difficult-to-treat lymphomas," said Bryan Campbell, senior vice president, Head of Commercial, Cell Therapy, Bristol Myers Squibb. Based on the U.S. Prescribing Information, in patients treated with Breyanzi and evaluated for efficacy, 85.3% responded to treatment, with 67.6% achieving a complete response, or CR, the company noted.

09:58 EDT Nano Nuclear Energy Inc trading resumes

09:55 EDT DBV sees one-for-two reverse ADS split effective on June 7 - DBV Technologies previously announced plans to change the ratio of its American depositary shares to its ordinary shares from the current ADS ratio of one ADS to one-half of one ordinary share to a new ADS ratio of one ADS to one ordinary share to be effective on or about June 3. The company now anticipates that the ADS ratio change will be effective on or about June 7. For the ADS holders, the change in the ADS ratio will have the same effect as a one-for-two reverse ADS split and is intended to enable the company to regain compliance with the Nasdaq minimum bid price requirement.

09:50 EDT Dell Technologies falls -18.1% - Dell Technologies is down -18.1%, or -$30.76 to $139.16.

09:48 EDT Elastic rises 13.8% - Elastic is up 13.8%, or $12.82 to $106.00.

09:47 EDT PagerDuty rises 16.4% - PagerDuty is up 16.4%, or $2.94 to $20.89.

09:44 EDT EMA recommends authorization for Valneva's chikungunya vaccine - The European Medicines Agency recommended granting a marketing authorization in the European Union for Valneva's Ixchiq, the first vaccine in the EU to protect adults 18 years and older against chikungunya. The vaccine is given in a single dose.

09:40 EDT Logistic Properties of The Americas trading resumes

09:38 EDT Vaccinex trading halted, volatility trading pause

09:36 EDT Citi Trends trading resumes

09:35 EDT Trxade Health Inc trading resumes

09:31 EDT Citi Trends trading halted, volatility trading pause

09:30 EDT Logistic Properties of The Americas trading halted, volatility trading pause

09:21 EDT Integrated Wellness Acquisition, Btab Ecommerce enter into BCA - Btab Ecommerce Group and Integrated Wellness Acquisition announced that they have entered into a definitive business combination agreement, BCA, providing for a business combination between WEL and BBTT. Upon completion of the Transaction, WEL will be renamed Btab Ecommerce Holdings, Inc and is expected to continue to be listed on NYSE. The Transaction values BBTT at an equity value of U.S. $250 million. Under the terms of the BCA, a wholly owned subsidiary of WEL will merge with and into BBTT, with BBTT surviving the merger and becoming a wholly owned subsidiary of WEL. WEL will issue 25,000,000 shares of its common stock, with each WEL share valued at $10 per share, to the BBTT shareholders as merger consideration, in exchange for all of the issued and outstanding shares of BBTT stock. It is currently anticipated that the transaction will close by the end of the fourth quarter of 2024.

09:18 EDT Chatham Lodging acquires Home2 Suites by Hilton Phoenix Downtown for $43.3M - Chatham Lodging (CLDT) announced that the company has acquired the recently opened, 148-room Home2 Suites by Hilton (HLT) Phoenix Downtown for $43.3M or approximately $293,000 per room. The institutional quality, six-story hotel sits in the heart of Downtown Phoenix and includes the historic Fuller Paint Company Building that houses the hotel's customized public spaces, including a signature food & beverage outlet. Upon stabilization, the acquisition is expected to produce RevPAR in excess of $150 and generate an estimated NOI yield over 9%.

09:11 EDT Astra Space receives deficiency notice from Nasdaq - Astra Space announced that it received a deficiency notice from Nasdaq indicating that, because Astra did not timely file its quarterly report on Form 10-Q for the quarter ended March 31 with the SEC, Astra was not in compliance with Nasdaq Listing Rule 5250, which requires Nasdaq-listed companies to timely file all required periodic financial reports with the SEC. As previously reported by Astra on its notification of late filing on Form 12b-25, filed with the SEC on May 14, Astra was unable to file its Form 10-Q without unreasonable effort or expense by the prescribed due date for such filing. As previously disclosed on Astra's current reports on form 8-K filed with the SEC on April 19 and April 26, respectively, Astra is not currently in compliance with Nasdaq Listing Rules 5450(a)(1) (the "Minimum Bid Price Requirement") and 5550(b)(1).

09:05 EDT Marsh McLennan acquires Perkins Insurance Agencies, terms undisclosed - Marsh McLennan announced the acquisition of Perkins Insurance Agencies, an Abilene, Texas-based independent agency. Terms of the acquisition were not disclosed. Founded in 1977, Perkins primarily provides commercial property and casualty and personal lines coverage to West Texas-based businesses, non-profits, and families, with specialized expertise in the oil and gas, trucking, farm and ranch, and restaurant industries. All Perkins employees, including Mark Perkins, CEO, will continue working out of their existing Abilene and Eastland, Texas, offices.

09:02 EDT Flex acquires FreeFlow, terms not disclosed - Flex announced it has acquired FreeFlow, a company serving global secondary markets with asset disposition and digital circular economy tracking and reporting capabilities. FreeFlow's B2B digital marketplace platform enables customers to sell surplus and returned inventory while protecting primary sales channels. The addition expands Flex's services for customers across multiple markets, including data center, enterprise, and lifestyle, to create additional revenue streams and accelerate sustainability through second life products.

09:02 EDT Safe Bulkers implements IMS in compliance with DryBMS Standards - Safe Bulkers announced that from June 1st, it is voluntary implementing a new computerized Integrated Management System in compliance with DryBMS Standards. The new IMS replaces the existing Safety Management System, is in line with Rightship RISQ3, focusing on Crew Welfare and SSI Code of Conduct, and ensuring the competence and commitment to the highest level of standards of our staff and fleet.

09:01 EDT Donerail says Penn could 'fetch up to double its current trading price' in sale - The Donerail Group, a shareholder of Penn Entertainment, disclosed that it sent an open letter to the company's board of directors, in which the investment adviser said it believes the company's "misguided interactive strategy and poor capital allocation have destroyed shareholder value, resulting in PENN trading at a steep discount to its intrinsic value." Donerail contends "PENN could fetch up to double its current trading price in the event of a sale," the firm added.

08:50 EDT Ecora Resources announces transaction in own shares - Ecora Resources announces that on 30 May 2024, it purchased 91,503 ordinary shares of 2p each in the Company on the London Stock Exchange through Peel Hunt LLP, in accordance with the terms of its share buyback programme announced on 27 March 2024. The Shares acquired will be held in treasury. Following the purchase, the Company will have 261,732,553 ordinary shares of 2p each in issue, of which 13,320,469 ordinary shares are held in treasury. Therefore, the total number of ordinary shares carrying voting rights will be 248,412,084.

08:35 EDT Sharps Technology CEO says demand for products is increasing - Sharps Technology issued a shareholder update from Robert Hayes, CEO, which read in part, " I want to share additional information about this week's transformative announcement and give you more insight into why the current agreement improves the deal terms we originally negotiated last September. Earlier this week, Sharps Technology signed an enhanced Asset Purchase Agreement with Nephron Pharmaceuticals to acquire the InjectEZ specialty syringe manufacturing assets in West Columbia, South Carolina. We also signed an accompanying five-year, $200 million syringe Sales Agreement with Nephron. Through these agreements, expected to close in about 60 days, Sharps will become the first fully dedicated, specialized polymer prefillable syringe manufacturing plant in North America. The facility will be on track to begin product deliveries in the second quarter of 2025, and we expect that our projected revenue should exceed $35 million for the first 12 months of sales. The InjectEZ and Nephron agreements were reworked to better support all parties involved, and as compared to the agreements announced last September, the signed deal includes several important advantages. Sharps is acquiring, for a significantly reduced price, a new state-of-the-art facility equipped with fully automated prefillable syringe system manufacturing, packaging, and distribution capabilities. The acquisition price is $35 million and there will be an assumption of certain related liabilities of up to $4 million. The five-year sales agreement included in the deal provides for Nephron's purchase of our next-generation copolymer PFS syringes manufactured at the SC plant as well as the qualification and future purchase of the 10mL SoloGard polypropylene disposable syringes produced at our Hungary facility. This assurance of supply is expected to support the planned expansion of the 503b operations at the Nephron site. Their minimum orders will include a range of Sharps products totaling over $200 million in sales during the five-year period. This gives Sharps a secure foundation to both support Nephron's core business requirements and expand our PFS sales throughout the larger pharmaceutical industry. Sharps' revenue is expected to exceed $35 million during the first 12 months of sales; the facility has sufficient additional capacity to generate revenue of more than $50 million in 2026, and has the capacity to potentially grow to over $100 million in revenue by 2028 within the currently standing facility. The recent FDA recalls and warnings as well as last week's tariff announcements impacting Chinese-manufactured syringes have created increased levels of interest in the Sharps family of syringe products. Additionally, there is an industry trend to transition from glass syringes to polymer prefillable syringes for injectable therapies, that continues to grow at an accelerated pace. Sharps is actively pursuing these sales opportunities and has been collaborating with medical product distributors, healthcare industry leaders in both branded and generic pharmaceuticals, and companies working within the rapidly expanding GLP-1 market space. We are currently involved in meaningful negotiations with a new customer who is a prominent American-based multinational pharma company focusing on treatments for both acute and chronic diseases, multiple major retail pharmacy chains, and several Fortune 500 healthcare supply distributors. Once the asset acquisition is closed, which is expected in about 60 days, Sharps will immediately move forward with the first phase of our manufacturing implementation plan. This phase includes the final facility buildout and planned upgrades to support the manufacture of pharmaceutical grade COC prefillable syringes on three state-of-the-art production lines. These lines will produce the highly demanded 10mL, 50mL, and 0.5mL/1mL syringe sizes. Product from the 10mL line will be qualified to ship early in the second quarter of 2025, and all three lines are expected to make saleable product by the fourth quarter of 2025. The second phase will execute a $9 million capital plan to install additional equipment to produce small volume COC syringes for the pharma market on a high-speed production line, with planned completion by July 2027. The $9 million investment will create the potential to bring in more than $35 million of additional revenue to the Company. The third phase of the expansion plan is focused on a $4.75 million investment to build a flex line capable of both producing a 5mL syringe and increasing Sharps capacity for 10mL production. This final buildout phase is expected to be completed by October 2027, and the investment of $4.75 million will create the potential to add more than $30 million to Sharps' annual revenue. These three manufacturing expansions will be completed within the facility as it exists today."

08:32 EDT Mullen Automotive appoints Alain Van Munster as VP EMEA - Mullen Automotive, announces a new key hire in support of its European commercial electric vehicles sales operations, in a move to solidify its position to capture a growing share of the European EV market for commercial applications. To spearhead its European expansion, Mullen has appointed Alain Van Munster as its new VP Europe Middle East and Africa, VP EMEA. Alain brings experience to the role, having spent over 25 years in the automotive and fleet industries across Europe, Asia and South America, including positions with Copart and Manheim. Mullen recently announced a new commercial EV fleet order for 40 all-electric Mullen-GO urban delivery vehicles with Switzerland-based Antidoto SA, a commercial upfitter whose key focus is on-demand food delivery companies

08:20 EDT Novartis announces its Phase III study of Scemblix showed 'superior efficacy' - Novartis presents results from the pivotal Phase III ASC4FIRST trial as a late-breaking abstract at the 2024 American Society of Clinical Oncology, ASCO, meeting. Novartis Scemblix Phase III data is the first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML. Scemblix demonstrated superior major molecular response, MMR, rates at week 48 compared to investigator-selected standard-of-care, SoC, tyrosine kinase inhibitors imatinib, nilotinib, dasatinib and bosutinib, and compared to imatinib alone in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Scemblix also showed a numerical improvement in MMR at week 48 vs. second generation TKIs. Additionally, Scemblix demonstrated a favorable safety and tolerability profile, with fewer adverse events and treatment discontinuations vs. both imatinib and 2G TKIs. The trial met both primary endpoints with clinically meaningful and statistically significant results. Nearly 20% more patients treated with Scemblix achieved MMR at week 48 vs. investigator-selected SoC TKIs and nearly 30% more patients achieved MMR at week 48 vs. imatinib alone1. Patients treated with Scemblix also achieved deeper rates of molecular responses compared with investigator-selected SoC TKIs and imatinib alone. In newly diagnosed patients, the safety profile was consistent with previous registration studies with no new safety concerns observed. The trial remains ongoing, with the next scheduled analysis at week 96 to evaluate the key secondary endpoint and additional secondary endpoints.

08:11 EDT Xiao-I signs agreement to implement advanced Live Chat AI system - Xiao-I is pleased to announce the signing of an agreement to implement its latest project, Live Chat, for a leading client in the automobile industry. This project aims to revolutionize the after-sales service landscape for the automotive industry through the deployment of intelligent customer service systems. The introduction of Live Chat is crucial for enhancing efficiency, reducing costs, improving customer experience, and elevating brand value in the after-sales service domain.

08:08 EDT Unusual Machines announces insider share purchases - Unusual Machines announced that key executives and directors have purchased additional shares of the company's stock. Between May 20 and May 30, 2024, CEO Allan Evans, COO Drew Camden, board member Sanford Rich, and board member Cristina Colon collectively acquired more than 40,000 shares through open market purchases.This recent insider buying brings insider ownership to approximately 64% of the Company, underscoring the leadership team's commitment to aligning their interests with those of the shareholders and reflecting their confidence in Unusual Machines' strategic direction and growth potential.

08:06 EDT Autonomix announces expected upcoming milestones - Expected Upcoming Milestones: Q2 CY2024: Announce topline results from first five patients in human clinical study evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain; CY2024: Complete ablation device design intended for clinical use; CY2025: Complete development of ablation system and sensing catheter in preparation for human pivotal trial; CY2025: Launch combined sensing / ablation clinical trial; CY2026: De novo submission; and CY2027: FDA clearance.

08:06 EDT Autonomix expects cash to fund operations into Q1 of 2025 - The Company estimates its current cash resources is sufficient to fund its operations into, but not beyond, the first quarter of calendar year 2025.

08:04 EDT Iterum announces FDA acceptance of resubmission of oral sulopenem NDA - Iterum Therapeutics announced that the U.S. Food and Drug Administration has acknowledged receipt of the resubmission of the New Drug Application for sulopenem etzadroxil/probenecid for the treatment of uncomplicated urinary tract infections in adult women. Under the Prescription Drug User Fee Act, the FDA has deemed the Company's NDA resubmission to be a Class II complete response which has a six-month review period from the date of resubmission. As a result, the FDA has assigned a PDUFA action date of October 25, 2024. The resubmission includes additional evidence from the REASSURE clinical trial, conducted under Special Protocol Assessment agreement from the FDA, comparing oral sulopenem to oral Augmentin in adult women with a uUTI, demonstrated that oral sulopenem was non-inferior to Augmentin for the primary efficacy endpoint of clinical and microbiologic response at the test-of-cure visit for patients with an Augmentin susceptible pathogen, with the difference in the overall success rate demonstrating statistically significant superiority of oral sulopenem versus Augmentin.

08:02 EDT PodcastOne appoints Merriman to board of directors - PodcastOne (PODC), a subsidiary of LiveOne (LVO), announced the appointment of Jon Merriman to its Board of Directors. Jon Merriman currently serves as Chief Business Officer for B. Riley Financial (RILY), a diversified financial services platform, as well as Senior Managing Director, Investment Banking, with B. Riley Securities, the firm's investment banking arm.

08:01 EDT Red Violet's FOREWARN partners with Santa Barbara Multiple Listing Service - FOREWARN, a red violet company, announced that Santa Barbara Multiple Listing Service will offer FOREWARN services to its 1,700+ members it serves throughout the Santa Barbara area to promote proactive real estate agent safety. Available both online and through a mobile application, FOREWARN analyzes billions of data points and provides users with the ability to mitigate risks by verifying identity, searching for criminal histories, and validating information provided by potential clients.

07:40 EDT Li Auto announces results of annual general meeting - Li Auto announced that each of the proposed resolutions submitted for shareholder approval as set forth in the notice of annual general meeting dated April 23, 2024 has been adopted at its annual general meeting of shareholders held in Beijing, China today. After the adoption of the Proposed Resolutions, all corporate authorizations and actions contemplated thereunder are approved, including, among other things, that Xing Wang and Mr. Zhenyu Jiang are re-elected as directors of the Company, and the directors of the Company are granted a general mandate to issue, allot, and deal with additional Class A ordinary shares or equivalents and a general mandate to repurchase the Company's own shares, respectively, on the terms and in the periods as set out in the AGM Notice.

07:37 EDT Soho House board determines transaction not in best interest - Soho House issued the following statement: "As previously announced, the Board of Directors of the Company established an independent Special Committee of the Board (the "Special Committee") in the fall of 2023 to evaluate certain strategic transactions, which included potentially becoming a private company. This was instigated because the Company received interest from a party that conditioned a proposal on certain Class B holders rolling over their equity interests in the Company as part of a transaction. The offer received from the party was at a value that reflected a substantial premium over the current trading price. After thorough review by the Special Committee and its independent advisors, the Special Committee concluded that the offer did not adequately reflect the value of the Company and was not in the best interests of its public stockholders. Consequently the Special Committee has requested that the Board dissolve the Special Committee, which it has done. The Board has the ability to establish such a committee in the future. The Company also announces today its intention to hold an Investor Day later this year at which it intends to update investors on its long-term growth plans." As a reminder, in February 2024 the Board approved a new $50 million share repurchase authorization.

07:33 EDT FSD Pharma wins petition to confirm arbitration awards against Raza Bokhari - FSD Pharma announces that on May 29, 2024, the United States District Court for the Eastern District of Pennsylvania confirmed FSD Pharma, Inc.'s Petition to Confirm Arbitration Awards entered against Dr. Raza Bokhari by a Canadian arbitrator in 2022. Pursuant to the Federal Rules of Civil Procedure, FSD will now move for entry of final judgment against Bokhari, as follows: USD $147,301.04, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied. CAD $31,912.55, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied. CAD $15,000.00, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied. CAD $2,814,229.15, plus interest at a rate of 6% per annum from May 7, 2023 until the date the Judgment is satisfied. In July 2021, FSD's board of directors terminated Bokhari, its former CEO. Bokhari filed an arbitration challenging this termination in Ontario, Canada. After years of litigation and an eight-day evidentiary hearing, the Arbitrator ruled against Bokhari and issued three awards against Bokhari in favor of FSD, including an award for damages and awards for FSD's fees and costs incurred in the arbitration. FSD's Petition to Confirm the Arbitration Awards was filed in the United States District Court for the Eastern District of Pennsylvania under the Convention on the Recognition and Enforcement of Foreign Arbitral Awards, June 10, 1958, 21 U.S.T. 2517, 330 U.N.T.S. 3. In its opinion granting FSD's Petition, the District Court found that Bokhari did not offer any valid basis under the New York Convention for the Court to deny enforcement of the arbitration awards against him.

07:32 EDT Rekor Systems unveils new capabilities for Rekor Discover platform - Rekor Systems announced the unveiling of a series of new and significant capabilities in its leading AI-driven traffic analytics platform, Rekor Discover. These will be showcased at the upcoming National Travel Monitoring Exposition and Conference 2024, taking place June 2-5 in Boise, ID. NaTMEC 2024 is a premier industry event for Federal and State Departments of Transportation, traffic agencies, and roadway engineering professionals across the US. This event will provide decision-makers across the traffic and transportation industry a pivotal opportunity to experience and evaluate the new features of Rekor Discover as they gather in person for the first time in four years to explore and experience the latest traffic and transportation technology advancements.

07:29 EDT SciSparc granted European Patenton antimicrobials - SciSparc announced that the European Patent Office granted the Company's patent application titled "Compositions and Methods of Potentiating Antimicrobials". This is in addition to the patent titled "Compositions and Methods of Potentiating Antimicrobials" previously granted by the United States Patent and Trademark Office. This patent grant bolsters the Company's intellectual property portfolio, extending the protection of its global patent holdings.

07:05 EDT Ecarx's Antora 1000 computing platform to power Geely Galaxy E5 SUV - ECARX Holdings (ECX) announced that its Antora 1000 computing platform will power Geely's (GELYF) Galaxy E5 SUV, which debuted today. ECARX Chairman and CEO, Ziyu Shen, said, "Demand for our cutting-edge computing platforms is growing as automakers increasingly recognize the significant value our solutions offer. The Antora 1000 not only provides a smooth and enjoyable driving experience for Geely users, but also lowers engineering costs, allowing Geely to rapidly bring the vehicles to market. Our unique ecosystem of partnerships with the likes of SiEngine plays a critical role in driving technological innovation across the industry."

07:04 EDT AirNet Technology announces purchase of 6,218 units of Bitcoin Miner S21 - AirNet Technology, formerly known as AirMedia Group, announced that the company entered into a sales and purchase agreement with an unaffiliated third party for the purchase of 6,218 units of Bitcoin Miner S21 on May 30. The aggregate purchase price for these miners is approximately RMB177.2M.

07:02 EDT Ionis reports 'positive' results from Phase 3 OASIS-HAE, OASISplus studies - Ionis Pharmaceuticals announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema demonstrating significant and sustained reduction in mean monthly HAE attack rates and continued attack rate improvement of greater than 90% with one year of treatment for both monthly or every two-month dosing. Patients who switched to donidalorsen from prior prophylactic treatment also showed 62% further reduction in mean monthly HAE attack rates from baseline, and 84% of patients who switched reported a preference for donidalorsen. Donidalorsen had a favorable safety and tolerability profile across both studies, including when self-administered via an auto-injector. Results will be presented in three late-breaking oral presentations at the 2024 European Academy of Allergy and Clinical Immunology Annual Congress in Valencia, Spain. Based on these data, Ionis is pursuing regulatory approval of donidalorsen as a potential treatment for HAE.

07:01 EDT Verve Therapeutics CSO Andrew Bellinger steps down, Troy Lister to succeed - Verve Therapeutics announced that Troy Lister, Ph.D., currently serving as Verve's senior vice president, research and early development, has been appointed chief scientific officer, effective June 21, 2024. Andrew Bellinger, M.D., Ph.D., who has served as CSO since 2019, will step down from this role and serve in an advisory capacity.

06:27 EDT UBS completes merger of UBS AG and Credit Suisse AG - UBS Group announces that it has completed the merger of UBS AG and Credit Suisse AG. The completion of the merger within the expected timeline was facilitated by the strong support from regulators across the globe. Credit Suisse AG has been deregistered in the Commercial Register of the Canton of Zurich and has ceased to exist as a separate entity. UBS AG has succeeded to all the rights and obligations of Credit Suisse AG, including all outstanding Credit Suisse AG debt instruments. The transition to a single US intermediate holding company is planned for June 7, with the merger of Credit Suisse AG and UBS Switzerland AG continued to be expected in the third quarter of 2024, both subject to remaining regulatory approvals.

06:05 EDT Immuron announces board changes - Immuron advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective 5/31. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. The company announces the appointment of Dr Jeannie Joughin as a Non-Executive Director, effective from June 1.

06:01 EDT BitFuFu names Calla Zhao as CFO, effective May 29 - BitFuFu announced the appointment of Calla Zhao as CFO, effective May 29. Calla Zhao has served as BitFuFu's financial controller since September 2021. Prior to joining BitFuFu, she served as head of finance at GGG Limited, an investment division of a conglomerate, from 2017 to 2021, and as an auditor at KPMG from 2005 to 2011.

05:22 EDT Regeneron, Sanofi report FDA extension of target action date for Dupixent review - Regeneron (REGN) and Sanofi (SNY)announced the FDA has extended by three months the target action date of its priority review of the supplemental Biologics License Application, or sBLA, for Dupixent as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease, or COPD. The revised target action date is September 27. The FDA did not raise any concerns regarding the approvability of Dupixent for this indication. The FDA had requested additional analyses on the efficacy of Dupixent in the BOREAS and NOTUS pivotal trials. Based on the submission of these analyses earlier in May, the agency has now determined that this additional information constituted a major amendment to the sBLA and extended the target action date accordingly. Regeneron and Sanofi are confident that the additional analyses strongly support the approval of Dupixent in COPD with evidence of type 2 inflammation, and are committed to working with the FDA to bring Dupixent to patients living with uncontrolled COPD as quickly as possible. Additionally, submissions for Dupixent in COPD are currently under review with regulatory authorities around the world, including the European Union and China. Recently, the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion and recommended the approval of Dupixent as an add-on maintenance treatment in adults with uncontrolled COPD characterized by raised blood eosinophils. The potential use of Dupixent in COPD is currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority.

05:15 EDT AbbVie reports CHMP opinion recommending approval for risankizumab - AbbVie announced that the European Medicines Agency's, or EMA's, Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion recommending the approval of risankizumab for the treatment of adults with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional or biologic therapy. The recommended induction dose is 1200 mg intravenous, followed by a maintenance dose of 180 mg or 360 mg subcutaneous, based on individual patient presentation. The final European Commission decision is expected in the third quarter of 2024.

05:08 EDT Clarivate enters strategic partnership with HealthWise Data - Clarivate announced a strategic partnership with HealthWise Data, a healthcare data and analytics firm bridging the gap between clinical outcomes and Social Determinants of Health, or SDoH, domains. The collaboration integrates SDoH attributes into the Clarivate Real-World Data repository, offering patient insights and enabling life science, healthcare and research professionals to enhance patient outcomes and healthcare equity.